Loading
A phase 1/2 trial of BPX-501 T cells in acute lymphoblastic leukaemia, acute myeloid leukaemia, non-Hodgkin lymphoma and myelodysplastic syndromes / neoplasms, run by Bellicum Pharmaceuticals, active and no longer recruiting.
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant is a phase 1/2 interventional study registered as NCT03301168 by Bellicum Pharmaceuticals, with 120 participants enrolled, started 2014-04 and due to reach its primary completion in 2021-05-11. Interventions recorded: BPX-501 T cells and Rimiducid.
Shares Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute lymphoblastic leukaemia, Acute myeloid leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute lymphoblastic leukaemia, Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia in children, Acute lymphoblastic leukaemia, Acute myeloid leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Acute lymphoblastic leukaemia, Acute myeloid leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute lymphoblastic leukaemia, Acute myeloid leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.